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ABSTRACT 
It’s not fully understood why some children wheeze with viral infections, and why some 
develop severe asthma. In this study we compared two study groups; children presenting with 
acute wheeze (AW) before the age of four and age-matched healthy controls (HC), and we 
investigated factors that might contribute to increased vulnerability for airway infections and 
risk of later asthma development.  
In Study I we identified several hereditary and environmental risk factors in the AW 
group, including significantly lower vitamin D levels and recurrent episodes of viral wheeze 
compared with the HC group. Rhinovirus (RV) was the most common virus detected. 
Bacterial co-infections were also common at the acute visit in the AW group. 
In Study II we investigated which subtypes of RV were detected during the acute 
phase, and the change in RV-specific IgG1 between the acute visit and a follow-up three 
months later. It is currently debated whether or not RV-C is more pathogenic than RV-A and 
RV-B. RV-C was the most frequently detected subtype, but we found no correlation between 
RV subtypes and clinical symptoms, or RV-specific IgG1 increase at follow-up. Children with 
an increase in specific IgG1 against both RV-A and RV-C, reported the longest duration of 
respiratory symptoms, indicating a possible synergistic effect of two RV subtypes and 
possibly an increased risk of asthma. 
Recently, CDHR3 has been identified as an asthma susceptibility gene, and it encodes the 
RV-C receptor, cadherin-related family member 3. In Study III we investigated CDHR3 
rs6967330 G>A genotype in the AW and HC groups, and AG/AA was found to be 
overrepresented in the AW group. Furthermore, reduced mRNA levels for CDHR3 were shown 
in children with acute wheeze.  
The chitinase like protein YKL-40 has been associated with airway remodeling, and 
severe asthma in school-children. In Study IV we investigated blood YKL-40 at the acute,    
3-month and 1-year follow-up visits. We studied the distribution of the genetic variant 
rs4950928 (-131C>G) in the gene encoding YKL-40, CHI3L1. The distribution was similar in 
the AW and HC groups, although rs4950928 variants were found to strongly affect circulating 
YKL-40 levels. The levels of YKL-40 were higher in the AW children during acute wheeze and 
at the 3-month follow-up, but did not differ between the groups at the one-year follow-up visit. 
In conclusion, preschool children in the AW group had several environmental and 
hereditary risk factors for later asthma development, as well as lower levels of vitamin D.  
RV-C was detected in the majority of children in the AW group and co-infection with bacteria 
was common. The asthma susceptibility gene variant rs6967330 in CDHR3 was associated 
with wheeze, and reduced mRNA levels of CDHR3 were shown in children with acute 
wheeze. However, the proposed biomarker YKL-40 did not facilitate the identification of 
children with persistent airway inflammation. 
Several of our findings indicate that children with wheeze may constitute a group of 
children with an increased vulnerability, both immunologically and genetically, placing them 
at greater risk of developing asthma compared to the healthy, age-matched HC group.  
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1 INTRODUCTION 
Asthma is the most common chronic disease in children, about 14% of the world’s children 
had symptoms of asthma in the previous year, according to The Global Asthma Report of 
2014. (1) The number of individuals with asthma has been increasing for a long time, but a 
decrease in prevalence has been reported in recent years. (2, 3)  
Asthma has traditionally been considered an allergic disease, but a large proportion of 
children with early asthma/wheeze do not appear to be allergic. (1) In the majority of cases, 
wheeze in children is triggered by viral infection, (5) and it has been shown that children 
wheezing with rhinovirus (RV) infection in their first year of life have a 3-fold increased risk 
of asthma at six years of age, but children wheezing with RV in their third year of life, have a 
32-fold increase in asthma at school age. (4) The Global Asthma Report of 2014 (1) highlights 
the recommendation that “recurrent wheeze in infancy, especially when frequent and/or severe 
episodes are present, should no longer be regarded as a benign condition but as part of the 
spectrum of asthma”. (1)   
Today preschool children with wheeze have no reliable classification to predict outcome 
over time (5), and clinicians have no easily attainable tools or biomarkers to measure lung 
function or airway inflammation, and to assess risk of chronic asthma.  
The pathogenesis of asthma is heterogeneous with a complex interplay between the 
immune system, genetic factors and the environment. A large number of genetic studies have 
attempted to find genetic variants associated with the risk of childhood wheeze and asthma. In 
many cases, candidate chromosomal loci are discovered by genome-wide association studies 
(GWAS) using large subject cohorts, followed by further studies of genetic variants in 
candidate genes (single nucleotide polymorphisms (SNPs)).  
It is important to combine clinical, immunological and genetic research to find new 
insights into the prevention and development of asthma. Early identification of preschool 
children with recurrent wheeze who are at risk of developing chronic asthma could make it 
possible to provide more specific and earlier therapeutic interventions, which could hopefully 
interfere with the disease trajectory. 
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2 BACKGROUND 
2.1 WHEEZE 
It has been difficult to find agreement among definitions of preschool wheeze, since there is a 
large overlap in phenotypes (phenotype being defined as a description of physical 
characteristics including disease history, see 2.2). To add further complication, patients may 
also move from one phenotype to another over time. The term episodic (viral) wheeze has been 
proposed to describe children who wheeze intermittently and are well between episodes 
(usually children less than three years of age), and the term multiple-trigger wheeze for 
children who wheeze both during and outside episodes of infection. (5)  This classification has 
however been questioned, as many children change from one to the other if the classification is 
based on a retrospective questionnaire. (6)  
The underlying process of wheeze includes inflammation of the airways, mucus production 
and reversible tightening of the smooth muscles in the airway walls. The whistling sound is 
produced by the vibration of opposing walls in the narrowed airways, causing dyspnea and 
cough (Figure 1). In the Tucson Children's Respiratory Study (TCRS), (7) one of the first 
longitudinal assessments of the natural history of asthma, 1246 children were followed from 
birth, and it was found that 1/3 of all children had an episode of wheeze before the age of three 
years, and 14% still had wheeze or asthma at school age.  
 
Figure 1. The process of wheeze includes inflammation of the airways with contraction of 
smooth muscle, hypersecretion of mucus and mucosal edema, narrowing the caliber of the 
airways causing a whistling sound when exhaling. 
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It is not currently known why respiratory infections trigger symptoms of bronchial obstruction 
in some children, but not others (50% had not experienced any episodes of wheeze at the age 
of six in the TCRS). (7) Underdeveloped airways are considered to be an important factor that 
may cause wheeze during the first year of life, but children wheezing during the second year of 
life are at greater risk of continuing to have reduced lung function. (8) The persistence of lung 
function abnormalities in those who wheeze beyond the first year of life is suggestive of a 
different disease process, possibly early airway inflammation. (8, 9) Other well known risk 
factors for the development of wheeze and later asthma are parental asthma/allergy, early 
sensitization, exposure to tobacco smoke and specific characteristics of the immune system. (9, 
10) In a review article on risk factors for non-atopic asthma in children, 30 risk factors were 
evaluated in 43 different studies, and out of them only 3 risk factors showed consistent 
associations with non-atopic asthma/wheeze: family history of asthma/rhinitis/eczema, 
dampness/mold in the household, and lower respiratory tract infections during childhood. (11)  
2.2 GENOTYPE, PHENOTYPE   
A genotype is the sequence of the DNA code that determines a specific characteristic of an 
individual, such as eye color, blood group or various hereditary diseases. Genotypes interact 
with environmental factors (e.g. exposure to smoke, viruses or starvation) resulting in 
expression of a certain phenotype (e.g. asthma or allergies). 
2.3 GENE EXPRESSION 
Proteins are the link between genotype and phenotype. Protein formation starts with the 
transcription of genes in the DNA to form messenger RNA (mRNA). The mRNA is then 
translated into polypeptides/proteins (Figure 2).   
 
Figure 2. Gene expression: a gene in the DNA is transcribed into messenger RNA (mRNA). 
This mRNA is then translated into a protein. (©2011 Pearson Education Inc.) 
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2.4 VITAMIN D 
Vitamin D is known to regulate calcium absorption and bone health, but recently the effect of 
vitamin D and its metabolites on other extra-skeletal functions and associations with chronic 
inflammatory diseases, including asthma, have come into focus. 
2.4.1 Vitamin D metabolism 
25(OH)D, is used to clinically assess vitamin D status. It can be formed in two ways in the 
human body; cholesterol in the skin is transformed by UVB sunrays (290-315 nm) to vitamin 
D3 (cholecalciferol), and in the gut vitamin D2 (ergocalciferol) is extracted from foods such as 
fish, mushrooms and fortified milk. Both of these inactive forms (vitamin D2 and D3) are 
transported in plasma to the liver to form the pre-hormone 25(OH)D (calcidiol).  
The active hormone, 1,25 dihydroxyvitamin D3 (calcitriol), is formed from 25(OH)D in the 
kidneys, stimulated by parathyroid hormone, and inhibited by high plasma levels of calcium 
and phosphate. (12) Calcitriol binds to the vitamin D receptor (VDR) in the nucleus of cells, 
and activates a nuclear transcription factor which regulates the gene transcription of many 
hundred genes (Figure 3). (12) VDR is expressed by many cell types throughout the body. 
 
 
 Figure 3. The metabolism of vitamin D 
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2.4.2 Optimal 25(OH)D levels 
The association between 25(OH)D, calcium regulation and bone health has been known since 
the beginning of the last century, yet reference values are still being discussed. (13) The levels 
to define the lower limits of 25(OH)D are levels that maintain normal calcium homeostasis. 
The most common definition of a normal vitamin D range has been a concentration of 
25(OH)D of 25-75 nmol/L (10 -30 ng/mL). It is known that children need to have >50 nmol/L 
(20 ng/mL) to avoid the risk of developing Rickets (14), and a 25(OH)D concentration of ≥50 
nmol/L is also recognized as an optimal level for adults. (14, 15)  
Vitamin D insufficiency is now commonly defined as 25(OH)D levels of 25-50 nmol/L, and 
deficiency is defined as levels of less than 25 nmol/L. 
Levels of the active hormone 1,25-dihydroxyvitamin D3 cannot be used for measuring vitamin 
D status, as it has a short half-life (hours) and levels are regulated by other factors such as 
serum parathyroid hormone (PTH). Therefore the level of 1,25-dihydroxyvitamin D3 can be 
normal or elevated as a result of secondary hyperparathyroidism, even in the presence of 25-
(OH)D deficiency. (12) 
2.4.3 Risk factors for 25(OH)D deficiency 
During the last decade, it has been shown exactly how prevalent 25(OH)D deficiency is 
worldwide, with high rates of 25(OH)D deficiency reported both in children and adults. (13, 
16)  
There is a clear relationship between latitude and levels of vitamin D detected. (16) For people 
living at latitudes higher than 35° (Stockholm is situated at 59° North), few UVB photons 
reach the earth’s surface from September to April, leading to a higher risk of vitamin D 
deficiency or insufficiency during half of the year for this population (Figure 4). (16, 17)  
 
 
 
 
 
Figure 4. For individuals living at latitudes above 35°, few UVB photons reach the earth’s 
surface from September to April. 
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Other factors associated with vitamin D deficiency/insufficiency include: a change in lifestyle 
(less outdoor activities), an awareness of skin cancer (using sunscreen with a sun protection 
factor of 15 blocks approximately 99% of cutaneous vitamin D production), increased BMI, 
increased age, having dark skin (which requires longer time with UVB exposure compared to 
people with lighter skin to synthesize equivalent amounts of vitamin D), being exposed to air 
pollution (which can filter out UVB radiation), and finally, having renal or liver disease. (18, 
19) 
2.4.4 Vitamin D and asthma 
Epidemiological studies demonstrate that suboptimal level of 25(OH)D are associated with 
recurrent viral respiratory infections, (20) and asthma. (18, 21, 22)  
The mechanisms whereby 25(OH)D is protective against asthma may be observed as early as 
the in utero period, when vitamin D plays a role in lung growth and maturation. (23) Vitamin 
D is also important for both innate and adaptive immune responses. The epithelium in the lung 
has the ability to locally convert inactive 25(OH)D to the active 1,25-dihydroxyvitamin D3 
leading to increased expression of genes important for innate immune defenses (24, 25) and 
activation of locally produced antimicrobial peptides (AMPs). (22) The vitamin D receptor is 
expressed on B cells, T cells and antigen presenting cells, all capable of synthesizing the active 
vitamin D metabolite, and thus vitamin D has the capability of acting locally, and 
independently of PTH levels. (25, 26)  
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2.5  RHINOVIRUS 
Rhinovirus (RV), also known as the common cold virus, belongs to the Enterovirus genus, 
within the Picornaviridae family, and is one of the smallest viruses. It was discovered in the 
1950s and was first classified into A and B species, (27) but in 2006 a third species, RV-C was 
discovered. (28) There are currently 74 known subtypes of RV-A, 26 subtypes of RV-B, and at 
least 50 subtypes of RV-C. (29, 30) Most RV grow best in temperatures between 33–35°C (as 
in the upper respiratory tract) and usually cause only mild symptoms, but some grow equally 
well at 37°C (as in the lower respiratory tract) and might be the cause of more severe 
respiratory symptoms involved in asthma exacerbations, as well as acute bronchiolitis and 
wheeze in young children. (29, 31) Despite 50 years of trying to develop a vaccine against RV 
the antigenic heterogeneity amongst the >150 RVs has been a major barrier resulting in little 
progress. (53)  
2.5.1  Rhinovirus structure 
Rhinoviruses have a genome composed of single-stranded positive RNA (the viral RNA 
functions as mRNA and can be directly translated into viral proteins within the host cell) and 
are non-enveloped viruses with capsids that express four viral proteins (VPs); VP1, VP2, VP3, 
and VP4. These proteins are arranged in overlapping fashion to form an icosahedral structure, 
with VP1, VP2, and VP3 expressed on the surface of the capsid while VP4 is located on the 
internal side of the capsid (Figure 5). (30, 32) 
 
 
 
 
 
Figure 5. Model of a rhinovirus with capsids that express four viral proteins VP1, VP2, VP3, 
and VP4 forming an icosahedral structure, with VP1, VP2, and VP3 expressed on the surface 
and VP4 located on the internal side of the capsid. (©Viral Zone 2008, Swiss Institute of 
BioInformatics) 
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2.5.2 Rhinovirus receptors 
RV-A and RV-B are also classified according to major or minor groups, depending on the 
receptor used to bind to human respiratory epithelial cells. Major group RVs (90% of all RV, 
both RV-A and RV-B) bind to the intercellular adhesion molecule 1 (ICAM-1) receptor and 
minor group RVs (all RV-A) bind to the low-density lipoprotein receptor (LDL-R).  
 Until recently, the RV-C receptor was unknown, but it has now been proposed that CDHR3, a 
cadherin-related family member protein, may function as the RV-C receptor. (30, 33, 34) 
CDHR3 is a member of the cadherin family of transmembrane proteins with an, as yet, 
unknown biological function. Cadherins are involved in homologous cell adhesion processes 
that are important for epithelial cell-cell interactions and tissue differentiation (34-37).  
2.5.3 Genetic regulation of the RV-C receptor  
The gene coding for the RV-C receptor, CDHR3, is the asthma susceptibility gene CDHR3, 
located on chromosome 7q22. It was recently discovered to be associated with a specific 
asthma phenotype characterized by recurrent, severe exacerbations occurring between 2 and 6 
years of age in a genome-wide association study. (34). It has been suggested that the gene 
variant rs6967330 A/G in CDHR3 could be a risk factor for RV-C wheezing illnesses since it 
has been found that the risk rs6967330-A allele can increase RV-C binding and virus 
replication in HeLa cells that synthesize CDHR3. (33, 34) 
2.5.4 Rhinovirus and asthma 
The significance of early RV infections in the development of wheeze and subsequent asthma 
is under investigation. There could be a critical time period early in life, when RV infections 
may change the pattern of the immune reaction (38-40), or this might be true only in a 
subgroup of susceptible children with impaired lung physiology or antiviral responses. (41-43)  
The pathophysiology of RV infection has some unique characteristics. The primary site of 
inoculation is the nasal mucosa and the infection involves only a small portion of the 
epithelium causing histamine release and nasal discharge. The virus does not cause any 
destruction of airway epithelial cells, but disrupts the tight junctions between cells destroying 
our first line of defense, the epithelial barrier. (44) Gaps within epithelial layers allow 
cytokines, immune cells and further viruses and bacteria to penetrate deeper into the airways, 
causing a massive upregulation of inflammatory mediators in the host. RV infections are often 
described as a “cytokine disease”. (45)  
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2.5.5 Immune response against rhinovirus 
The clearance of a RV infection is dependent on both rapid innate immune responses 
(involving interferons, macrophages, antimicrobial peptides) as well as the humoral (B-cells 
with antibody formation) and cell-mediated immune responses (T-cells with cytokine 
regulation). (46) 
Interferons (IFNs) are cytokine protein mediators, important for the early innate antiviral 
immune response. (47) In asthmatic individuals, impaired virus-induced IFN expression has 
been shown, and IFNs are important both during recovery from RV infections as well as in the 
prevention of virus-induced exacerbations. (42) Defective IFN secretion has also been seen in 
non-atopic children with viral-induced wheeze. (48) 
The antiviral effector mechanism of the adaptive immune system involves the formation of 
neutralizing antibodies, whereby serotype-specific neutralizing serum antibodies (IgG) as well 
as secretory antibodies (IgA) develop. (49) Since they occur weeks after the infection, the 
humoral immune responses with antibody formation are thought to be most important for 
preventing RV infection. Antibody production in natural RV infections occurs on average in 
only 50% of patients. (49) 
In contrast to the specific antibody response, T-cells show serotype cross-reactivity and can be 
activated either by serotype-specific or shared viral epitopes. (50, 51) Rhinovirus belonging to 
the major-group RV has been shown to directly infect and activate human T-cells without 
intervention of antigen presenting cells (APCs; monocytes, macrophages, or B-cells.). (52) 
This activation results in cytokine release from T-cells and activation of eosinophils, and the 
subsequent triggering of other inflammatory effector cells, ultimately causing exacerbations of 
airway disease. (52)   
 
2.6 CHITINASE-LIKE PROTEIN YKL-40 
Today, we do not have adequate biomarkers (defined as biological substances that can be 
detected and measured in for example blood or tissue, such as specific cells, gene or gene 
products) that are able to reflect chronic inflammation within the airways. However, one 
protein that has shown potential for this purpose is the chitinase-like protein YKL-40. 
Chitin is the second most abundant polysaccharide on earth after cellulose, and a component of 
the cell walls of fungi and of the external skeleton of insects such as grasshoppers and 
cockroaches, and arthropods such as crabs and lobsters. Chitinases are hydrolytic enzymes that 
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break down the glycosidic bonds in chitin. (54) Humans do not produce chitin, but have two 
functional chitinases, Chitotriosidase (CHIT1) and acidic mammalian chitinase (AMCase), as 
well as the structurally-related chitinase-like protein, YKL-40. YKL-40 lacks chitinase activity 
and specific cell surface or soluble receptors have not yet been identified. The name of the 
protein YKL-40 derives from its molecular weight (40 kDa) and the one letter code for its three 
N-terminal amino acids, tyrosine, lysine, and leucine.  
2.6.1 YKL-40 production  
The main cell types able to secrete YKL-40 include a small group of highly differentiated 
tissue macrophages (type I) with pro-inflammatory properties, but with no production of anti-
inflammatory cytokines and a low capacity for phagocytosis. (55, 56) Neutrophil granulocytes, 
which share a common progenitor cell with macrophages, store YKL-40 in specific granules, 
and release them after full activation at inflammatory sites. (57) Other cell types that express 
YKL-40 are, chondrocytes, synovial cells, vascular smooth muscle cells and hepatic stellate 
cells. (56) 
2.6.2 YKL-40 function   
YKL-40 levels are known to show a slow increase during adulthood and a steep increase after 
the age of 70, even in healthy elderly individuals. (57) Elevated levels of YKL-40 have been 
associated with multiple human inflammatory diseases including severe asthma in school age 
children (58) and adults. (59) The exact biological function of YKL-40 is not known, but it has 
been suggested that YKL-40 could act as an opsonin with a role in the human immune 
response (60) and be involved in airway remodeling due to its effect on smooth muscle 
proliferation  and correlations with sub-epithelial fibrosis and bronchial wall thickness. (61)  
2.6.3 Genetic regulation of YKL-40 
The chitinase-3-like-1 gene (CHI3L1) located on chromosome 1q32.1 encodes the protein 
YKL-40. Several single nucleotide polymorphisms in this gene have been identified, and the 
genotype variant CHI3L1rs4950928 (-131C>G) has been associated with hyper responsiveness 
in the airways and reduced lung function (62) suggesting that genetic variations in CHI3L1 
may influence serum YKL-40 levels and the risk of asthma.  
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3 AIMS 
We hypothesize that certain preschool children with wheeze have a specific genetic 
disposition that results in a vulnerability towards airway infections, and that certain viruses 
may trigger signs of remodeling at an early age. 
The specific aims of this study were: 
I. To identify risk factors for preschool wheeze, including specific sensitization 
patterns and vitamin D status. 
II. To analyze subtypes of rhinovirus in relation to clinical symptoms and serological 
response after an acute episode of wheeze. 
III. To investigate the gene variant CDHR3 rs6967330 G>A and mRNA expression of 
CDHR3 in relation to RV subtypes, RV-specific IgG1 increase and clinical 
symptoms in preschool children with acute wheeze and at a follow-up visit. 
IV. To investigate distribution of the gene variant CHI3L1 rs4950928 (-131C>G), and 
its effect on the chitinase-like protein YKL-40, and whether YKL-40 is a possible 
biomarker of relevance to acute wheeze.  
V. To identify possible markers of risk for chronic asthma in preschool children 
presenting with acute wheeze.  
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4 METHODS 
4.1 STUDY DESIGN  
The present thesis is based upon a longitudinal prospective study of a group of preschool 
children with acute symptoms of obstructive airways/wheeze and an age matched control 
group of healthy children, see Figure 6 for study design. The group of children with wheeze 
will be followed yearly until the age of seven, and this thesis covers the first year with one 
follow-up after approximately three months and one follow-up a year after inclusion.  
The study was approved by the regional board of ethics at Karolinska Institutet (Dnr  
2008/378-31/4 and 2014/399-31/3). 
 
Figure 6. Study design 
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4.2 STUDY MATERIAL (I-IV) 
The children with acute wheeze (AW) included in the study were recruited by the study doctor 
and the research nurse when attending the Pediatric Emergency Department or after admission 
to the Pediatric Emergency Ward as a result of their symptoms, at Astrid Lindgren Children’s 
Hospital, Stockholm, Sweden, between October 2008 and September 2012.  
Age-matched, healthy control children (HC) were recruited by the research nurse at the 
Children’s Surgical Daycare Ward, Astrid Lindgren Children’s Hospital during the same time 
period. The HC group had minor day surgery performed (retentio testis/hernia 44%, 
cystoscopy/micturating cystourethrogram 32%, hypospadias/circumscision/phimosis 9%, 
laparoscopy 12%, minor incisions 4%). For inclusion and exclusion criteria, see Table 1. 
 
Table 1. Inclusion and exclusion criteria 
 Inclusion criteria Exclusion criteria 
Children with 
wheeze/asthma 
 Age 6-48 months 
 Presenting at the 
emergency with 
acute symptoms of 
wheeze 
 
 Prematurity (birth before 36 gestational w.)  
 Any chronic disease 
 Any simultaneous complications such as 
sepsis, bacterial pneumonia or diabetes at the 
time point of inclusion 
 
Healthy children  Age 6-48 months 
 
 Prematurity (birth before 36 gestational w.)  
 History of bronchial obstruction/asthma 
 Known sensitization to airborne allergens 
 
4.3 PROCEDURES 
4.3.1 Inclusion of children with wheeze at the first acute visit (I-IV) 
At the Pediatric Emergency Department or ward at Astrid Lindgren Children’s Hospital, the 
diagnosis of wheeze was based on a clinical diagnosis made by the treating physician at the 
Pediatric Emergency Department and treatment was with salbutamol inhalation. After the 
enrolment criteria were confirmed by the study doctor or research nurse, the guardians of 
children with AW were informed about the study and after written informed consent was 
provided, samples of venous blood were drawn following local anesthesia (EMLA cream, 
Astra Zeneca, Sweden) and nasal swab tests were obtained for virus detection. In addition, 
study children enrolled between September 2010 and September 2012 also had nasal swab 
tests for bacteria at the emergency visit. (Table 2) 
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4.3.2 Follow-up visit after 2-4 months and after 12 months (I-IV) 
After approximately 2-4 months, the children with AW came back to the study doctor for a 
follow-up visit. The guardians were asked to fill out a standardized questionnaire concerning 
demographic factors, hereditary factors for asthma and allergy, birth weight, smoking during 
pregnancy, contact with furry animals, eczema, reported food intolerance, time with breast 
feeding and previous history of respiratory infections. The children underwent a clinical check-
up and the study doctor carried out a structured interview with the guardians concerning the 
number of days the children had suffered respiratory symptoms, the number of acute visits and 
hospitalizations and medication since the acute visit. This was also confirmed using medical 
journals. The children had blood samples drawn after local anesthesia (EMLA cream, Astra 
Zeneca, Sweden) and again, nasal swab tests for virus detection were obtained. (Table 2) 
Approximately 12 months after the acute visit, the children with AW had a second follow-up 
with the same clinical check-up, structured interview concerning time spent with symptoms 
and medication, and blood samples were drawn. (Table 2) 
4.3.3 Inclusion of control children (I, III-IV) 
The guardians of the healthy control children were informed about the study by the research 
nurse. After they had provided written informed consent, blood was drawn at one occasion 
from the children at the same time as an intravenous line was inserted prior to surgery and 
anesthesia. Guardians were asked to fill out the same standardized questionnaire about 
hereditary factors, lifestyle and environmental factors as the study children with AW. (Table 2) 
Table 2. Procedures at visits 1, 2 and 3 in children with acute obstructive airway disease (AW), 
 and on one occasion in a group of healthy age-matched control children (HC). 
 
Procedures 
AW 
Visit 1 
n=156 
AW 
Visit 2 
n=130 
AW 
Visit 3 
n=120 
HC 
 
n=101 
Age in months, median (min-max) 18 (6-42) 20 (8-46) 30 (18-57) 18 (6-44) 
Clinical investigation  156 130 120  
Standardized Questionnaires  130  101 
Nasal swab samples for bacteria                          881    
Virus analysis on a 15 virus platform (I)                           154 121   
Blood count; neutrophils/eosinophils (I-IV) 149 120 106 101 
Total IgE in serum (I-IV)  124  81 
Specific IgE in serum (Phadiatop/Fx5 ) (I-IV)  124  81 
25(OH)D (I)  114  99 
RV subtype analyze (II) 108 102   
Levels of  RV specific IgG1 and IgA antibodies (II)           120 120   
CDHR3 rs6967330 genotype (III)  122  94 
Levels of YKL-40 (IV)       128 120 95 101 
CHI3L1 rs4950928 genotype  (IV)  123  95 
1Of the 88 children tested for bacteria at the acute visit, 76 children came back for the first follow-up visit and 
were included in Study I. 
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4.4 LABORATORY ANALYSES  
4.4.1 Blood count and IgE (I-IV) 
All blood samples from both groups of children (drawn at the acute visit, the first and second 
follow-up visits for the AW group, as well as at the time of surgery for the HC group) were 
analyzed for total blood counts including hemoglobin, thrombocytes, leukocytes, and 
differential numbers of basophils, neutrophils and eosinophils according to standard 
procedures at the Karolinska University Hospital Laboratory, Stockholm, Sweden. 
Levels of total IgE antibodies and allergen specific IgE antibodies against common airborne 
allergens (Phadiatop®; birch, timothy, mug worth, cat, dog, horse, moulds (Cladosporium 
herbarum), dust mites (Dermatophagoides pteronyssinus, Dermatophagoides farina) and food 
allergens (fx5®; cow’s milk, egg white, soy bean, peanut, cod fish and wheat) (Thermo Fisher 
Scientific, Copenhagen) were analyzed in blood samples from the AW group (taken at first 
follow-up visit) and the HC group. Sensitization was defined as levels of specific IgE 
antibodies ≥0.35 kUA/L. 
4.4.2 Vitamin D (I)  
Levels of 25(OH)D were measured in serum samples from the AW group obtained at the first 
follow-up visit, approximately 3 months after the acute visit, and in samples from the HC 
group. The method for analysis used at the Karolinska University Hospital Laboratory was a 
standard procedure involving direct, competitive chemiluminescence analysis (CLIA, DiaSorin 
inc, USA). Levels of 25(OH)D <75 nmol/L (30 ng/mL) were used as cut off for suboptimal 
levels of vitamin D (insufficiency), and levels < 25 nmol/L (10 ng/mL) for deficiency. 
4.4.3 Bacterial nasal swab tests (I) 
The presence of bacteria was examined in 88 children at the acute visit, using a nylon nasal 
swab (Copan Eswab, Copan Diagnostics Ltd, Murrieta, California, USA) that was transported 
within two hours at room temperature to the Department of Clinical Microbiology, Karolinska 
University Hospital, for qualitative aerobic culture on solid media with Haemophilus 
influenzae, Streptococcus pneumoniae, Moraxella catarrhalis and beta-haemolytic 
Streptococci of groups A, C and G as target bacteria.  
4.4.4 Virus analyses on a 15 virus platform (I) 
The nasal swabs for virus detection were collected by the research nurse at the acute visit and 
at the first follow-up visit after 2-4 months on children in the AW group, and transported 
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within two hours after collection in a standardized virus medium (Sigma-Virocult, Medical 
Wire & Equipment Co Ltd, Corsham, Wiltshire, UK). The swabs were analyzed according to 
standard procedures by real time PCR using a 15 virus platform developed in 2007 (including 
Adenovirus, Bocavirus, Coronavirus (229E, HKU1, NL63), Influenza A, Influenza A/H1N1 
and Influenza B,  Parainfluenza virus (1,2,3), Metapneumovirus, Enterovirus, Rhinovirus and 
Respiratory Syncytial virus) (63), and then stored in the biobank at the Department of Clinical 
Microbiology, Karolinska University Hospital. 
4.4.5 Subtyping of rhinovirus species (II, III) 
Nasopharyngeal swab samples from the AW group were obtained at the acute visit and at the 
follow-up 2-4 months later (see 4.4.4). After the first analysis (described above), these were 
stored in the biobank at the Department of Clinical Microbiology, Karolinska University 
Hospital until subsequent nested PCR analyses and sequencing were performed at the 
Immunology and Allergy Unit, Department of Medicine, Solna, Karolinska Institutet, 
Karolinska University Hospital Solna, in collaboration with the Division of Immunopathology, 
Department of Pathophysiology and Allergy Research, Center of Pathophysiology, 
Infectiology and Immunology, Medical University of Vienna, Austria. This procedure has been 
described previously (paper II). 
4.4.6 Rhinovirus specific IgA and IgG1 (II, III) 
Levels of species-specific IgA and IgG1 antibodies against the three known rhinovirus subtypes 
(RV-A, RV-B and RV-C) were measured in serum taken at the acute visit and the first follow-
up visit in the AW group as described previously (paper II).  In short, ELISA plates were 
coated with recombinant VP1 proteins from three representative strains of the RV-A subtype 
(RV-A2, RV-A16, RV-A89), one from the RV-B subtype (RV-B14) and one from the RV-C 
subtype (RV-YP) and human serum albumin (HSA). The reactivity to human serum albumin, 
as determined in serum from each patient was used as a negative control.  
The optical density (OD) values corresponding to the levels of bound antigen-specific 
antibodies were measured using an ELISA reader (Dynatech, Denkendorf, Germany). The 
change in OD values were calculated as the OD value at the acute visit subtracted from the OD 
value at the follow-up visit (∆OD). A change in OD value ≥0.1 in antibody levels between the 
acute visit and follow-up visit were considered to show an immunological response to 
rhinovirus. 
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4.4.7 Genotyping (III, IV) 
In both groups of children, the gene variants rs6967330 G>A located in the CDHR3 gene (III) 
and rs4950928 (-131C>G) located in the CHI3L1 gene (IV) were analyzed using TaqMan 
allelic discrimination on the ABI Prism 7500 detection system according to the manufacturer’s 
protocol (Thermo Fisher Scientific, Waltham, MA, USA). Genotype calls were achieved from 
both children with wheeze (n=122 and n=123 respectively) and control children (n=95 and 
n=96 respectively). 
4.4.8 CDHR3 and levels of mRNA expression (III)  
In a randomly selected subgroup of 50 children with wheeze, CDHR3 expression was analyzed 
in blood leukocytes from blood samples taken at both the acute visit and the follow-up visit 
after 2-4 months. Likewise, CDHR3 expression was analyzed in 17 healthy control children 
using a multiplexed TaqMan assay on the 7500 Fast Real-Time PCR system (Thermo Fisher 
Scientific, Waltham, MA, USA). Reactions were multiplexed in order to analyze CDHR3 
(Hs00541677_m1) and the endogenous control (cyclophilin A [PPIA]: Hs99999904_m1) in 
the same well (Thermo Fisher Scientific, Waltham, MA, USA) according to manufacturer’s 
recommendations. 
4.4.9 Levels of YKL-40 (IV) 
Levels of the chitinase-like protein YKL-40 were measured in plasma samples collected at the 
three visits in children with AW (the acute visit; n=95, 2-4 months follow-up; n=98, and one-
year follow-up; n=83 children. 54 children came to all three visits), and also in plasma from the 
HC group (n=94) by ELISA (3) according to the manufacturer’s instructions (Human Chitinase 
3-like 1 DuoSet ELISA Development Kit, R&D Systems, Abingdon, United Kingdom). In 
short, two different dilutions were made for each sample from which an average was obtained, 
and all samples were analyzed in duplicate, in random order, and presented as ng/mL. The 
detection limit of this assay was 31 pg/mL, inter-assay variability was 3%, and intra-assay 
variability was 14%. 
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5 STATISTICS 
Paper I-II: The χ2-test was used to examine proportional differences between binary data. 
Variables with unadjusted p-values ≤0.05 were then analysed in multivariate logistic regression 
analyses for potential confounders. For normally distributed continuous variables (blood 
count), an unpaired t-test was used to compare between-group means. For data that did not 
show a normal distribution, the non-parametric independent samples Mann-Whitney U test (for 
two groups) and Kruskal-Wallis median test (several groups) were used to compare 
distribution and medians. SPSS software (version 19-22 IBM Corporation, Armonk, NY, 
USA) (I-4) was used for all statistical analyses. 
Paper III: The χ2 test was used to examine proportional differences for CDHR3 gene variants in 
the AW and HC group. In addition, the χ2 test was used when comparing the AW group 
according to variants of CDHR3 rs6967330 genotype in relation to basic characteristics, 
medication, hospitalization, emergency visits until follow-up visit, PCR detection of RV and 
species-specific IgG1 increase against RV. Variables with p-values ≤0.05 in the χ2-test were 
considered significant. The independent samples Mann-Whitney U test was used to compare 
medians and distributions between the two groups. The Wilcoxon signed rank test was used to 
compare paired samples not following a normal distribution (the expression levels of mRNA 
acute and at revisit). Spearman Rank correlations were performed to analyze correlations 
between CDHR3 expression at the acute visit and follow-up visit in children with different 
genotypes and clinical symptoms.  SPSS software (version 22, IBM Corporation, Armonk, 
NY, USA) was used for statistical analyses. Allelic association was calculated in Haploview 
software version 4.2 (22). Expression levels of mRNA in each sample were determined by the 
comparative Ct method of relative quantification (64). (Relative quantification analyze 
changes in gene expression in a given sample relative to a control sample.) Data was presented 
as 2-∆Ct. 
Paper IV: Basic comparisons were performed using GraphPad Prism statistical software (La 
Jolla, CA, USA). YKL-40 levels did not have a normal distribution and were presented as 
median with interquartile range and non-parametric tests were performed; the Wilcoxon 
Signed Rank test for paired datasets, the Mann Whitney test for un-paired datasets and the 
Spearman Rank test for univariate correlations. Regression analyses were performed using 
SPSS software following log transformation of YKL-40 levels (version 22, IBM Corporation, 
Armonk, NY, USA). 
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6 MAIN RESULTS 
6.1 CLINICAL CHARACTERISTICS (I-IV) 
In total, 156 children with acute wheeze (AW) were enrolled at the Pediatric Emergency 
Department or Ward at Astrid Lindgren Children’s Hospital. An age matched group of 101 
healthy children (HC) were recruited at the Children’s Surgical Daycare Ward during the same 
time period. Of the children belonging to the AW group, 80% were admitted to the ward for in-
house treatment and 82% received an oral steroid burst of 4 mg betamethasone within 24 hours 
of admission. The majority had experienced wheeze before, and 52% had previously been 
diagnosed with asthma, but 22% of the children were experiencing their first episode of 
wheeze. At the acute visit, 42% had ICS (17% continuously), at the first follow-up visit 75% 
had ICS (42% continuously) and at the one-year follow-up 90% had ICS (37% continuously). 
The age distribution was similar in both groups at the acute visit (median 18 months (range 6-
42 vs 6-44 months)).  There was however a male dominance in the HC group compared with 
the AW group (79% vs 65%, p=0.02), this was due to the fact that the dominating diagnoses at 
the Children’s Surgical Daycare Ward were related to the male genitalia (see Study material 
4.2). (Table 3) The gender distribution remained within the AW group at the second follow-up 
visit (79% vs 68%). 
6.2 HEREDITARY AND ENVIRONMENTAL FACTORS (I) 
A standardized questionnaire regarding family history, environmental factors and prior 
illnesses was collected from 130 children that came back for the first follow-up visit in the AW 
group and for all 101 children in the HC group at inclusion. 
The AW group had significantly more parents with pollen allergy and more mothers with 
asthma, more maternal smoking during pregnancy, less exclusive breastfeeding time (the 
children had infant formula from birth) and higher childcare center attendance (p≤0.04 for all, 
Table 3).  
Children in the AW group had significantly more recurrent respiratory infections, earlier 
reported infections with respiratory syncytial virus (RSV) and bacterial pneumonias compared 
with the HC group (p≤0.01). At the clinical follow-up of 130 children after a median of 11 
weeks, (range 6 to 31 weeks), 76% had had one or several episodes of respiratory infections, 
38% had made an unplanned visit to a doctor because of acute wheeze and 15% had been re-
admitted to the hospital because of respiratory problems since the initial emergency visit. 
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6.3 SENSITIZATION (I, II, IV) 
The percentage of children with total serum IgE>100 kUA/L was similar in the AW group and 
the HC group (19% vs 13%, p=0.30). No significant difference was found between the two 
study groups with regard to sensitization towards airborne allergens (phadiatop, 9 % vs 4%, 
p=0.14.) In the AW group, 4 children reported allergic rhinitis; one reacted towards birch, one 
against cat and two against grass. All children were asymptomatic in the HC group. There was 
no difference in the number of children sensitized to food allergens (fx5) between the groups 
Table 3. Clinical characteristics of 130 preschool children with acute wheeze (AW) compared with 
101 healthy age matched controls (HC). 
 AW 
(n=130) 
HC 
(n=101) 
 
p-value 
Male,  %  68 79 0.02 
Age 6-24 months, % 75 69 0.30 
Median age in months (min-max)1 17 (6-42) 18 (6-44) 0.34 
Mother caucasian, % 82 76 0.22 
Father caucasian, %   85 76 0.1 
Asthma mother, % 27 7 <0.01 
        “     father, % 12 7 0.23 
Pollen allergy, mother, % 36 13 <0.001 
    “         “        father, % 28 9 <0.001 
Breastfeeding, total time ≥ 4 months 68 75 0.30 
No exclusive breastfeeding time, % 28 16 0.04 
Attend Childcare Center, % 73 53 <0.01 
Smoking during pregnancy mother, % 11 3 0.02 
Current smoking at home, % 22 20 0.62 
Furred pets at home, % 25 22 0.5 
Current eczema, % 18 7 0.02 
Reported clinical food reaction, % 15 3 <0.01 
>6 respiratory infections a year, % 66 19 <0.01 
Reported RSV infections ever, % 31 5 <0.01 
Bacterial pneumonia ever2, % 8 0 0.01 
Total IgE ≥100 kU/L (%) 19 13 0.30 
Total IgE, kU/L (median (min-max)) 26.6 (0.7-810.7) 13.5 (0.2-414.1) 0.03 
Neutrophils, 109/L (median (min-max))2 
  acute visit 
 
7.1 (1.6-27.8) 
 
2.6 (0.9-11.7) 
 
<0.001 
  3-month follow-up 3.4 (0.5-12.9)  0.30 
  1-year follow-up 3.5 (0.1-9.4)  0.22 
Eosinophils,109 /L (median (min-max))3 
  acute visit 
 
0.1 (0.0-4.6) 
 
0.2 (0.1-2.1) 
 
<0.001 
  3-month follow-up 0.3 (0.1-6.8)  0.001 
  1-year follow-up 0.3 (0.1-1.1)  0.06 
1 Median age at the inclusion of the study of the 130 children that came back for the second visit and 
healthy control children  
 2Definition of bacterial pneumonia: fever >38°C, CRP >50 mg/L and confluent infiltrates on X-rays 
and treated with antibiotics, or diagnosis made by the pediatrician at the Emergency Ward.  
3 Blood cell counts were analyzed in n=96 control children, and in children with acute wheeze;  
n =149 at visit 1, n=120 at visit 2 and n=106 at visit 3 
  21 
(24% vs 20%, p=0.49).  Of children reporting clinical food reactions in the AW group (n=28), 
30% (n=8) were positive in the fx5 panel (>0.35 kUA/L). Two of the children in the HC group 
reported clinical food reactions, and one of these had an fx5>0.35 kUA/L. Nine children in the 
AW group showed positive IgE against peanuts and one of the children in the HC group. 
6.4 VITAMIN D (I) 
Serum levels of 25(OH)D were analyzed in blood samples obtained at the first follow-up visit 
from 114 of children in the AW group, and from 99 children in the HC group. 25(OH)D 
insufficiency with values <75 nmol/L was found in 39% (n= 44) of children with acute wheeze 
and in 24% (n=24) of the control children (p=0.04). A significant difference between the two 
groups was also observed using 25(OH)D levels as a continuous variable (p=0.03) (Figure 7A). 
There was a significant correlation between 25(OH)D levels and age (p<0.001). When the age 
groups 6 to 24 months and 25 to 46 months were studied separately, the older children had a 
significantly lower median vitamin D level in both study groups (p<0.001 for both, Figure 7B). 
Atopy levels with specific sensitization, eczema or reported food allergies were not 
associated with 25(OH)D insufficiency. The degree of bacterial or viral colonization was no 
different in children with 25(OH)D insufficiency compared to 25(OH)D sufficient children.  
 
 
   A.                                                         B. 
 
Figure 7. Levels of 25(OH)D in a group of children with acute wheeze and a healthy control 
group (p=0.03) (A) and in two age groups (p<0.001 for both) (B). 
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6.5 DETECTION OF VIRUS ON A 15 VIRUS PLATFORM AND BACTERIA (I) 
Virus was detected in 69% of 154 children tested in the AW group at the acute visit. 
Rhinovirus was most common (36%, n= 56), followed by respiratory syncytial virus (17% 
n=26) (Table 4). Bacteria were found in nasopharyngeal cultures from 70% (n=52) of the 88 
children tested. Moraxella catarrhalis was the most common bacterial finding, detected in 59% 
(n=52) of the children followed by Streptococcus pneumoniae (24%, n=21) and Hemophilus 
influenzae (19%, n=17).  When detected, M. catarrhalis was the single pathogen in 40% 
(n=21) of cases. (In paper I, the results are reported on the 130 children that came back for a 
second follow-up visit, of which 76 children were tested for bacteria.) 
 
 
 
 
 
 
 
 
 
 
Table 4. Viruses detected in 154 children during the acute 
episode of wheeze, and in 121 children at the 3 month 
follow-up visit. 
 
 
Virus 
Acute 
visit 
n=154 
n         % 
Follow-
up visit, 
n=121 
n           % 
Adenovirus  7 4 1 1 
Bocavirus 17 11 6 5 
Coronaviruses  9 6 6 5 
Enterovirus  30 19 5 4 
Non typable Entero-/ Rhinovirus 9 6 0 0 
Influenza A virus 1 1 1 1 
Parainfluenzaviruses 1-3 5 3 1 1 
Rhinovirus 56 36 17 14 
RS virus 26 17 4 3 
Metapneumovirus  4 2 2 2 
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6.6 RHINOVIRUS SPECIES (II, III) 
Of 108 children in the AW group tested for different RV species (RV-A, RV-B or RV-C), 74% 
(n=80) had detectable RV (RV-A 20%, n=16, RV-B 5%, n=4 and RV-C 61%, n=49, Figure 8). 
A combination of two different RV species was detected in ten children (nine with RV-A and  
-C, one with RV-B and -C), (Figure 8). At the follow-up visit after approximately three 
months, RV species was reanalyzed in 102 of the children, and of these only 4 were positive 
for RV, all with a different species compared to the acute visit.  
 
Figure 8. Rhinovirus subtypes detected during an acute episode of wheeze in 108 preschool 
children. 
6.7 RV-SPECIFIC IgG1 AND IgA ANTIBODIES (II, III) 
Of the 120 children in the AW group with measurements of RV-specific IgG1 and IgA levels at 
the acute visit and at the follow-up visit three months later, 92% (n=111) had prior IgG1 
antibodies against one or several RVs. An increase in RV-specific IgG1 antibodies was seen in 
61% (n=73) of the children at the follow-up visit (Table 5). The results of the IgA analyses 
were similar to IgG1, but lower (Table 5). The initial levels of RV-IgG1 measured at the acute 
visit did not correlate with reported time with respiratory symptoms until the follow-up visit.  
Irrespective of the RV species detected at the acute visit, an increase in IgG1 against RV-A 
(RV89, 16 and/or 2), or against both RV-A (RV89, 16, 2) and RV-C (RV-YP)  
were significantly associated with more respiratory symptoms (p=0.03 for children with RV-
A (RV89,16 and/or 2) and p=0.007 for children with both RV-A (RV89,16 and/or 2) and RV-
C (RV-YP), Figure 9).  
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Figure 9. Irrespective of RV species detected at the acute visit, children showing a RV-specific 
IgG1 increase against RV-A and both RV-A and RV-C reported the longest time with 
respiratory symptoms until follow-up. 
Table 5. Presence and increase in RV-specific IgA and IgG1 antibodies in  
120 preschool children with acute wheeze and at follow-up (median 11 weeks later). 
 
 
 
 
RV subtypes 
IgA 
at acute visit 
n=108 (90%) 
IgA increase 
at follow-up 
n=68 (57%) 
IgG1 
at acute visit 
n=111 (92%) 
IgG1 increase 
at follow-up 
n=73 (61%) 
n % n % n % n % 
RV-A89 104 87 45 38 102 85 62 52 
RV-A16 97 81 42 35 103 86 39 32 
RV-A2 104 87 50 42 106 88 47 39 
RV-A89,16,2 96 80 38 32 100 83 42 35 
RV-B14 65 54 23 19 73 61 20 16 
RV-C 80 67 29 24 93 78 26 22 
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6.8  CDHR3 rs6967330 G>A AND mRNA EXPRESSION (III) 
DNA was available from 122 preschool children with AW and 94 children from the HC group 
in whom the rs6967330 G>A polymorphism in the CDHR3 gene was analyzed. Significant 
associations were found between the rs6967330-A allele and AW, and on a genotypic level 
AG/AA was associated with AW (p= 0.0006 and p=0.002, respectively).  
We also analyzed the level of expression of CDHR3 in a subgroup of 50 children in the AW 
group compared to 17 children in the HC group. CDHR3 mRNA levels at the acute visit were 
0.56 times the expression level in the HC group (p=0.001, Figure 10). At the follow-up visit,  
2-3 months later, the same children in remission showed less of a reduction in CDHR3 mRNA 
expression compared to that observed during the acute phase (p=0.001, Figure 10). Children in 
the AW group with the AA/AG genotype expressed less CDHR3 mRNA at the acute visit than 
the follow-up visit (p=0.005).  
At a clinical level, significantly more children with the AG/AA genotype (42%, n=31) 
compared to the GG genotype (20%, n=10) required emergency care due to respiratory 
symptoms between the acute visit and follow-up visit 2-3 months later (p=0.01).  
No correlation between CDHR3 mRNA and RV species detected at the acute visit could be 
found, but children with increased RV-specific IgG1 levels against both RV-A and RV-C at the 
follow-up visit showed significantly reduced levels of CDHR3 expression (p=0.006). 
 
 
 
 
 
 
 
 
Figure 10. Comparing levels of CDHR3 mRNA expression in children during an acute episode 
of wheeze and at follow-up after 2-3 months, as well as in a group of age-matched healthy 
controls. Data are presented as 2-∆Ct. 
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6.9 CHI3L1 rs4950928 C>G AND YKL-40 (IV) 
DNA was available from 123 children in the AW group and 96 children from the HC group 
and the gene variant CHI3L1 rs4950928-131C>G was analyzed. Genotype frequency was 
found to be similar in the two groups. (CC 63%, CG 31%, GG 6% respective CC 55%, CG 
39%, GG 6%, p=0.51). CHI3L1 rs4950928 affected YKL-40 in all subjects, with highest levels 
present in those with the CC genotype (p<0.001). 
Serum levels of YKL-40 were examined in the AW group (n=128 from the acute visit, n=120 
children from the second visit 3 months later and n=95 children after 1 year) and in 100 
children from the HC group. The AW group had higher levels at the acute visit (median 14.7 
ng/ml, p<0.001) and 3-month follow-up (median 15.9 ng/ml, p<0.001) compared to the 1-year 
follow-up (median 11.9 ng/ml).  
YKL-40 levels in the HC group (median 13.6 ng/ml) tended to be lower than in the AW group 
during the first acute visit (p=0.07) and the second 3-month follow-up (p=0.04), but were no 
different at the 1-year follow-up.  
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7 DISCUSSION 
7.1 STUDY DESIGN AND INCLUSION CRITERIA 
This thesis is based on the first year of a longitudinal prospective study of a group of preschool 
children with wheeze (AW) and an age-matched group of healthy control children (HC). The 
children were aged 6 months ≤4 years at inclusion. They were approached in the emergency 
unit during an airway infection causing an acute episode of wheeze. The children in this study 
will have yearly follow-up visits until the age of seven, which offers a unique opportunity to 
follow clinical and immunological changes, and investigate genetic variants with the overall 
aim to find early biomarkers for the development of chronic asthma. The HC group will also 
have a second follow-up visit when they are seven. The inclusion criteria were based on the 
fact that most children with wheeze before 4 years of age have not yet developed allergies and 
are found to have a neutrophilic airway inflammation,  (65, 66)  making it difficult in this 
thesis to evaluate the prognosis for risk of persistent asthma.  
The HC group was recruited at the Children’s Surgical Day-Care Ward where they had minor 
day surgery performed, and selection bias for this group of children related to the variables 
and outcomes used in this study seems unlikely in view of the inclusion criteria. In comparison 
with the BAMSE cohort study, (designed to study risk factors for asthma, allergic diseases and 
lung function in childhood), which covers children living in the same inclusion area in 
Stockholm, the proportion of children with parental allergy, lifestyle factors such as the 
presence of furry pets, breastfeeding and ethnicity did not differ to any major extent with the 
HC group in our study. (67, 68) 
The group of children in this study is small given that asthma as a disease is so heterogeneous, 
and the prevalence of severe asthma is low. The prevalence of asthma is reported to have 
increased continuously during primary school ages, with allergic sensitization and a family 
history of asthma being the most important risk factors. (69). In a study of 10 year old 
children in Norway, the prevalence of severe asthma was 0.5% in all 10 year olds, and 4.5% 
among current asthmatics. (70) Nevertheless, our group of wheezing children is at higher risk 
of developing asthma than the general population, and constitutes a valuable source of clinical 
and biological data, providing material for future studies on asthma development.  
7.2 CLINICAL CHARACTERISTICS (I) 
Environmental and hereditary risk factors for wheeze are well known, including maternal 
smoking during pregnancy, short breastfeeding time, high childcare attendance and allergy in 
mother and/or father (11), and these were also confirmed in our study as significant risk factors 
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in the AW group. Childcare attendance as a risk factor for asthma has however been debated. 
In earlier studies, it has been shown that children with greater exposure to other children at 
home or daycare were more likely to experience frequent wheeze at the age of 2 years, but less 
likely to have frequent wheeze from the age of 6 onwards. (71, 72) Childcare attendance before 
the age of 12 months seems to protect against later asthma development. (72)  
The most striking difference between the AW group and the HC group was the number of 
reported respiratory infections during the past year: the average number of expected colds in a 
preschool child is approximately 6 infections/year and this was reported by 58% of the AW 
group but only 19% of the control children (p<0.001). This difference indicates a vulnerability 
of the immune system in the AW group, possibly reflecting an impaired ability to clear virus 
and/or bacterial infections. Recent studies have pointed out that the number of episodes of 
wheeze before one year of age, but not the particular viral trigger, was associated with later 
asthma development (73).  
One may speculate about other environmental risk factors that could contribute to the 
wheezing phenotype of our AW group in the study. In the majority of cases, the children were 
living in areas north of Stockholm City. This area has several large, heavily trafficked roads as 
well as two airports. The control children lived in a more scattered area over the whole of 
Stockholm including the suburban areas on the south side without airports, since Astrid 
Lindgren Children’s Hospital is the only hospital with a pediatric surgery department in 
Stockholm. There is an increasing awareness of early-life exposure to traffic-related air 
pollution (TRAP) and increased risk of persistent wheeze, and long-term exposure to TRAP 
with asthma development. (74, 75) Of the 120 children that came back for the third follow-
up after a year, 90% had ICS medication and 37% took ICS medication continuously, 34% 
reported more than 100 days with inhaled β2-agonist use. 
7.3 ALLERGIC SENSITIZATION (I) 
Rhinovirus infections have been associated with wheeze and allergic sensitization, (76) and 
Jackson et al reported that sensitization to aeroallergens leads to viral wheeze, but viral 
infection does not lead to sensitization. (77) In our study the AW group reported significantly 
more clinical symptoms of food allergy than the HC group, but the number of children positive 
for allergen-specific IgE antibodies did not differ significantly between the groups.  In the AW 
group, 9% (n=11) were sensitized against aeroallergens, but 24% (n=22) were sensitized 
against food (6 children were sensitized against both), including 9 children with peanut allergy 
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(7%). Taken together these findings confirm a low prevalence of allergic sensitization in our 
group of children with viral wheeze. 
Interestingly, one of the children with very high levels of antibodies against peanuts in the AW 
group, had never to the parents knowledge tasted peanuts, and had never suffered a reaction, 
indicating another route of sensitization, possibly through external exposure. An association 
between peanut allergy and the intake of soy milk, skin rash and the use of skin preparations 
containing peanut oil has been reported. (78) Recent studies have found an independent effect 
of IgE sensitization towards food allergens and local and systemic markers of inflammation in 
asthma, independent of allergy against aeroallergens (79, 80), but no association between 
asymptomatic sensitization to food allergens and asthma suggesting that there may be other 
links between food allergy and asthma. (80) Twenty-six (20%) of the children with AW had 
eczema, and of these 6 were sensitized to food, but only two displayed clinical symptoms. The 
initiation of sensitization via cutaneous exposures has received a great deal of current attention 
due the recent discovery that mutations in the filaggrin gene, which induce a defect in the skin 
barrier, have been linked to both atopic dermatitis and asthma, as well as peanut allergy. (81-
83) One may speculated that recurrent RV infections could contribute to sensitization not only 
by affecting the airway epithelia, but also by having a systemic effect on the immune system 
with aggravated eczema symptoms as a result. Intervention studies have shown a reduction in 
the risk of developing childhood asthma in high risk children if both dietary and environmental 
allergen exposures are reduced, but not if only aeroallergens are avoided. (84)   
7.4 VITAMIN D (I) 
We found that 25(OH)D concentrations were inversely correlated with age, which is in 
agreement with previous studies on children and adults. (85, 86) There seems to be a drop in 
25(OH)D levels after approximately 2 years of age in both the AW group and the HC group, 
which might be due to the fact that this is the time point/age at which free supplementation of 
vitamin D from childcare centers in Sweden comes to an end.  
The children in the AW group had significantly lower serum levels of 25(OH)D than the HC 
group, but the majority of the children could still not be regarded as showing vitamin D-
insufficiency, as only 4 of the children in the AW group and one in the HC group had levels 
below 50 nmol/L. The reference values for 25(OH)D are evaluated according to bone health, 
but evidence is still insufficient for other outcomes e.g. respiratory health. (15) It has been 
reported that other limits might be more correct, since the cell-regulatory actions of 1,25-
dihydroxyvitamin D3 are found at 25(OH)D concentrations higher than 75 nmol/L. (14)  
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One may speculate that children in the AW group with recurrent infections might have a 
dysfunction whereby vitamin D conversion to the active hormone 1,25-dihydroxyvitamin D3 in 
tissue is impaired, or whereby regulation of the vitamin D receptor (VDR) and the vitamin D 
binding protein (DBP) is somehow altered compared to the HC group. VDR activation by the 
binding of 1,25-dihydroxyvitamin D3 affects the expression of over 900 genes, and genome-
wide studies have identified several genes that contribute to 25(OH)D variability. (87) 
Dysregulation of the VDR may lead to exaggerated inflammatory responses associated with 
immune-mediated diseases such as Crohn’s disease and tuberculosis, characterized by an 
imbalance in helper T-cell development. Genetic variants in VDR have also been identified 
as risk factors for asthma. (88, 89) More detailed future investigations of DBG function may 
be important since the DBG has shown an association with circulating 25(OH)D concentration 
in healthy children. (90, 91) Tissue-specific production of 1,25-dihydroxyvitamin D3 that is 
important both for the innate and the adaptive immune systems, has been identified. (92)   
1,25-dihydroxyvitamin D3 may be involved in direct modulation of the T-cell antigen receptor, 
important in T-cell activation. (93) Furthermore, macrophages can convert circulating 
25(OH)D into 1,25 dihydroxyvitamin D3 during a bacterial infection thus inducing the 
expression of genes encoding antimicrobial peptides which are central to the innate immune 
response. (94)  
A difficulty in the diagnosis of vitamin D deficiency is the inconsistency between different 
measurement methods.  In our study, direct, competitive chemiluminescence analysis (CLIA; 
DiaSorin Inc, Stillwater, MN, USA) was used as a routine procedure at the Karolinska 
University Hospital Laboratory and this method has been reported to show a higher 
proportion of low values. (95) Other studies have also shown considerable differences in 
measurements compared with those obtained at a certified laboratory, and differences have 
even been observed between laboratories using the same assays. (96)  
Significant associations between lower vitamin D levels and a greater use of inhaled 
glucocorticoids have been shown, indicating that lower vitamin D levels could contribute to a 
more severe asthmatic condition. (97) In our study, we did not find a correlation between “time 
with steroid inhalation” and vitamin D levels in the AW group. 42% were treated with ICS at 
the acute visit (17% continuously), and at the first follow-up visit 75% had ICS (42% 
continuously). In this age group it is difficult to evaluate possible relationships between 
25(OH)D levels and steroid inhalation, since vitamin D levels decrease with age, and usually 
the children with recurrent wheeze begin ICS treatment after an episode severe enough to 
require a visit to the emergency department and meet a pediatrician, which is usually also after 
  31 
they began to attend childcare centers after one year of age. Steroid resistance might also be 
related to a more chronic airway inflammation, but it is known that even children with wheeze 
may not always respond to steroids. (98) 
7.5 VIRUS AND BACTERIA (I-III) 
7.5.1 Rhinovirus detection 
In this study, two different PCR-based methods have been used to detect RV using the same 
patient material. In paper I, the laboratory at Karolinska University Hospital used real time 
PCR with an established 15 virus platform (63) (n=154 children, 36% positive for RV) and in 
paper II, our collaborators in the Allergy and Pathophysiology Department at the Medical 
University of Vienna, Austria, used nested PCR to detect RV strains and to subtype them 
(n=108, 74% (n=80) positive for RV). A discrepancy in the results could be observed between 
the two methods; of the 108 children tested using the nested PCR method in paper II, only 36% 
(39/108) were positive according to the PCR technique used in the first paper.  It should be 
noted that children later subtyped with RV-C were often not positive in the first analysis with 
real time PCR, only 37% (n=22 of 59 children with RV-C in paper II) were found with this 
method, the percentages for detection of RV-A and RV-B found in paper II were 48% and 75% 
respectively of those in paper I. At follow-up the detection rate was the opposite, the real time 
PCR detected 17 children with RV and the nested PCR only 4 children. In a study comparing 
the relative sensitivity of a cross-section of published RV-specific PCR primers (most of which 
were first published before RV-C was reported), a high degree of variability in performance 
was found, and none of the pairs could detect all RVs in 2 panels of genotyped clinical 
specimens, suggesting that inefficient RV detection by PCR may be a problem both in the 
clinic as well as in research studies. (99)  
 
7.5.2 Rhinovirus and bacterial co-infections 
The contribution of bacterial colonization to the severity of respiratory symptoms is being 
discussed, and some studies have reported an aberrant immune response to bacteria in infancy 
in children with later asthma development. Both bacteria and viruses were independently 
shown to be associated with wheeze (100-102).  
Our current investigations regarding bacteria as co-pathogens, were similar to earlier 
studies performed on children with wheeze in Denmark (100). The distribution of bacterial 
detection in the Danish study was approximately equal for S. pneumoniae (46%), H. 
Influenzae (44%) and M.catarrhalis (50%). (100) Interestingly, in our study the presence of 
M.catarrhalis was the same as the Danish study, but  fewer cases were observed with              
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S. pneumonia and H. Influenzae  (59%, 24% and 19% respectively). There is a discussion 
concerning whether the introduction of pneumococcal vaccines in the general vaccination 
program can alter colonization patterns in children, and cause a selection and increase in 
colonization and infection by M. catarrhalis. (103) The children in the Danish cohort study 
were born between 1998-2001, and this was before vaccination against S.pneumoniae was 
introduced into the Danish vaccination program in 2007. (100, 104) In our study 25% of the 
children enrolled were born before 2009 when Sweden introduced vaccinations against 
S.pneumoniae. When looking at the pattern of bacteria in our study in children born before or 
after 2009, we found no difference (p=0.75 for M. catarrhalis, p=0.80 for H. Influenzae, 
p=0.49 for S. pneumoniae), which suggests that the introduction of vaccination against 
S.pneumoniae did not alter colonization pattern in our study children. 
In a study where children aged 4-12 years provided nasal samples over a period of 5 
consecutive weeks in the autumn, detection of RV increased the risk of detecting bacteria 
within the same sample or that obtained the following week. In particular, detecting            
M. catarrhalis alongside RV increased the likelihood of experiencing a cold and/or asthma 
symptoms compared with isolated detection of RV. (105) In our study, children with RV had 
M. catarrhalis as a co-pathogen in 59% of cases, and M. catarrhalis was also found alone in 
nine of children negative for RV, indicating the ability of this bacteria alone to induce 
wheeze.  It has recently been reported that epithelial cells infected with M. catarrhalis 
showed increased expression of RV compared with uninfected cells, and that M. catarrhalis 
can reduce antiviral defense functions of bronchial epithelial cells by diminished secretion of 
IFN-β and IFN-λ. (106) This may increase susceptibility to viral infections, and in our group 
also symptoms of wheeze.  
7.5.3  Rhinovirus species  
Differences in the pathogenicity of different RV-species is currently under debate. In general, 
RV-A and RV-C are a more common finding in children with wheeze, than RV-B, and RV-B  
is associated with milder disease, which might be a reason why RV-B is detected at a lower 
frequency in hospital-based studies (107). RV-C was discovered in respiratory samples of 
patients from New York with influenza-like illness in 2004, and in infants with bronchiolitis 
from Queensland hospitals in 2006 (108, 109) where it was reported to cause more severe 
lower respiratory tract infections than RV-A or RV-B. Recent reports however found that the 
clinical manifestations of infections appear to be similar between RV-A and RV-C. (110, 111) 
In our group of preschool children with acute wheeze, the reported time with symptoms until 
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follow-up visit was the same in groups with different species of RV, also in children with 
double virus species. 
7.5.4 Serum levels of RV-specific IgA and IgG1  
The antiviral effector mechanisms of the adaptive immune system involve the formation of 
neutralizing antibodies whereby serotype-specific neutralizing serum antibodies (IgG) as 
well as secretory antibodies (IgA) are developed in the airways. (49)  In our study, levels of 
RV-specific IgA and IgG1 in plasma were measured, both at the acute visit and at the follow-
up visit 2-3 months later. The reason IgG1 and IgA were examined was based on earlier 
experimental studies of RV infections in adults, performed by our collaborators in the 
Allergy and Pathophysiology Department at the Medical University of Vienna, where RV-
specific IgG1 and IgA were found to show the strongest responses. (112) No children with 
wheeze included in our study had an IgA-deficiency, but given that innate immunity in the 
nasal mucosa most likely relies upon secretory IgA, and our measurements were of serum 
levels, the interpretation of IgA levels is difficult and we did not include these results in the 
paper (II). IgG1 can remain elevated for years after a RV infection, making this easier to 
relate to reported illness. (113, 114) We found that children with increased RV-specific IgG1 
against RV-A and RV-C at the follow-up visit, reported the longest time spent with 
respiratory symptoms between the visits, which is similar to adults experimentally infected 
with RV where individuals with more severe manifestations of respiratory symptoms showed 
the highest increases in RV-specific IgG1 antibodies. (112) In our study, older children had 
the highest levels of RV-specific IgG1 antibodies at the acute visit, but their increase was not 
stronger compared with that of the younger children (paper II). It is not clear whether or not 
an increase in RV-specific antibodies is an indicator for risk of asthma later in life, but it is 
known that asthmatic individuals have higher levels of IgG1 antibodies against RV than non-
asthmatics. (115) 
7.6 CDHR3 AND mRNA EXPRESSION (III) 
In our study (III) we genotyped AW and HC children for the rs6967330 A>G polymorphism in 
the CDHR3 gene. The risk allele A was significantly overrepresented in the AW group, both at 
the allelic (A) and genotypic (AG/AA) level.  
In addition, we analyzed CDHR3 mRNA expression in a subgroup of 50 children from the AW 
group and 17 children from the HC group. Levels of mRNA expression were measured in 
white blood cells from both the first acute episode and the second follow-up visit 2-3 months 
later. Interestingly, in contrast to earlier findings on HeLa cells in vitro (33), the mRNA levels 
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for CDHR3 in children with AW with the AA/AG genotype were significantly reduced at the 
acute visit compared to the HC group, but at the follow-up visit 2-3 months later the same 
children in remission showed a smaller reduction in CDHR3 mRNA compared to HC. This is 
in agreement with a recent study of CDHR3 mRNA expression in human epithelial cells 
cultured ex vivo, where cells from asthmatics showed lower expression than cells from non-
asthmatics. (116)  Interestingly, they also showed that expression was further reduced by RV 
infection with RV-A16, and that levels correlated with RV infection. (116)  
We did not find an association between expression levels of CDHR3 mRNA and the RV 
species detected at the acute visit in our study, but children with increased RV-specific IgG1 
levels against both RV-A and RV-C at follow-up did show significantly reduced levels of 
CDHR3 at the acute visit compared to follow-up. This is in parallel with our earlier finding 
(paper II), where children with increased RV-specific IgG1 against both RV-A and RV-C at the 
follow-up visit reported most symptoms between the acute and follow-up visits. Since these 
results are from a subgroup of a small study, larger studies are needed to confirm the finding.  
Asthma has been associated with over a hundred different genes, but a major problem in many 
genetic studies is the lack of replication of results, only a subset of identified genes has been 
found to be associated with asthma in more than one study. (117) An exception however has 
been the finding that the ORMDL3 gene is associated with childhood-onset asthma 
worldwide. (118, 119)  
Again, our study highlights the difficulty in trying to investigate genetic findings, the degree of 
expression of an asthma susceptibility gene and the influence it has on clinical severity. It also 
points out the importance of cell-specific investigations when investigating expression levels. 
As acute wheeze primarily affects the airways, the most relevant samples would be, e.g. 
bronchial epithelial cells or bronchial biopsies. Blood is more accessible due to a less invasive 
sampling method, and changes in blood could be assumed to mimic the expression pattern in 
the airways.  Our attempts to draw conclusions from genetic findings, expression levels and 
clinical data have to be interpreted cautiously, but hopefully may provide ideas for larger 
studies in the future.  
7.7 CHI3L1 GENE VARIANT AND YKL-40 (IV) 
Levels of YKL-40 are associated with airway inflammation in both children and adults with 
asthma (58, 120), We therefore wanted to investigate whether this was also the case at an early 
age in a high-risk, preschool group of children with acute airway infection. The gene variant 
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CHI3L1 rs4950928 and protein levels of the chitinase-like protein YKL-40 were analyzed in 
the AW group and the HC group, and we found that rs4950928 variants strongly affected 
YKL-40 levels, but we did not find a difference in the distribution of rs4950928 genotypes 
among the AW and HC groups. Circulating YKL-40 levels were increased at the acute visit 
and the 3-month follow-up in children with AW compared to the HC group, but not at the one-
year follow-up suggesting that the serum YKL-40 may be increased during acute infections.  
Dividing children into those with and without more severe respiratory symptoms based on 
symptoms and treatment was generally not associated with higher YKL-40 levels. 
Interestingly, significantly higher YKL-40 levels were observed in children taking montelukast 
at the acute visit, which could indirectly suggest higher YKL-40 levels in a group of children 
with more severe airway disease requiring asthma medication, however, this difference was not 
observed at follow-up visits during remission. We therefore conclude that although YKL-40 
may be increased during an acute episode of airway inflammation, it is unlikely to be a useful 
biomarker of persistent wheeze in this age group, possibly because the biological processes in 
which YKL-40 is involved in chronic adult asthma are not occurring at this early age. 
In the present study, YKL-40 levels and circulating neutrophil numbers were found to 
correlate. This is in line with previous studies of schoolchildren with severe asthma. (56) 
Neutrophils are a known source of YKL-40, and are increased in the circulation during acute 
infections. (56) In studies of children with cystic fibrosis, a disease characterized by 
neutrophilic airway inflammation, the difficulty of trying to investigate local inflammation in 
the airways using a systemic blood test were highlighted as YKL-40 levels were high in the 
sputum but only moderately elevated in serum. (121) In adults, allergen challenge has been 
shown to cause local increases in YKL-40 as determined by increased sputum and BAL levels, 
but these changes were not mirrored in the circulation. (122) In addition, it has recently been 
shown that well differentiated human airway epithelial cells express CHI3L1, and mechanical 
stress during bronchoconstriction trigger epithelial cells and induce CHI3L1 expression leading 
to local secretion of YKL-40 protein. (123)  
Earlier studies have examined YKL-40 levels in very young children and found that levels are 
higher at birth and then plateau up to 5 years of age. (60) When we plotted serum YKL-40 
concentrations for the different patient groups divided into 6 month intervals, it did not reveal 
higher levels in the younger children, or an increase with age, suggesting that over the age span 
of 6 months to 4 years, YKL-40 levels do not seem to be affected by age. Even though YKL-
40 is not useful as a biomarker for risk of chronic asthma in this age group, our investigation 
has nevertheless contributed to knowledge of normal YKL-40 levels in preschool children. 
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8 MAIN RESULTS AND CONCLUSIONS 
In the first study (I) we found that the preschool children attending the emergency department 
with acute wheeze shared known hereditary and environmental risk factors such as a family 
history of asthma and allergy, maternal smoking during pregnancy, less exclusive 
breastfeeding time and higher childcare center attendance. Children with wheeze had lower 
vitamin D levels, significantly more clinical food allergies and recurrent airway infections 
which may indicate an impairment in the immune system and reduced ability to combat viral 
infections, along with an increased risk of developing allergies. In addition, we detected both 
viruses and bacteria in the majority of children with wheeze, possibly suggesting that bacterial 
colonization could contribute to the severity of respiratory symptoms.  
In the second study (II) RV was detected in nasopharyngeal samples in the majority of 
children with acute wheeze. RV-C was the most common finding, but symptoms and 
medication did not differ from children with RV-A infection. Children with an IgG1 increase 
against both RV-A and RV-C reported most respiratory symptoms until revisit, irrespective of 
the RV species found at the acute visit, possibly indicating synergistic effects of RV-A and 
RV-C and a more severe inflammation. 
In the third study (III) the asthma susceptibility gene variant CDHR3 rs6967330: G>A 
encoding the RV-C receptor cadherin-related family member 3, was analyzed. Carriers of the 
risk allele-A were found to be overrepresented in the AW group. Children with the AG/AA 
genotype showed the lowest levels of CDHR3 mRNA in the acute phase, as well as the largest 
differences in CDHR3 mRNA expression between the acute visit and follow-up, possibly 
indicating a group with increased vulnerability towards RV infections.  
Children with increased RV-specific IgG1 levels against both RV-A and RV-C at 
remission showed significantly reduced levels of CDHR3 expression during the acute phase 
compared to follow-up, possibly indicating synergistic effects of RV-A and RV-C and a more 
severe inflammation. 
In the fourth study (IV) the chitinase-3-like-1 (CHI3L1) rs4950928 genotypes were 
investigated and found to show a similar distribution in the AW and HC groups. Circulating 
levels of the chitinase-like protein YKL-40, encoded by the CHI3L1 gene, were elevated in the 
AW group compared with the HC group at the acute visit and at the follow-up visit three 
months later, but not at the one-year follow-up. These findings speak against YKL-40 as a 
useful biomarker of persistent wheeze in this young age group.  
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The levels of YKL-40 in serum in the present study were associated with the number of 
circulating neutrophils, indicating a reflection of a neutrophilic inflammation with an increase 
in the number of neutrophils, or possibly neutrophils producing more YKL-40. 
In conclusion, preschool children in the AW group had several environmental and hereditary 
risk factors for the later development of asthma, as well as lower levels of vitamin D. We 
investigated whether specific RV-species could contribute to a more severe form of wheeze, 
but did not find any associations between reported symptoms and detected species. Bacteria 
were identified as co-pathogens in the majority of children with wheeze, possibly indicating 
a synergistic effect of virus and bacteria, creating an excessive immune reaction in the 
airways of children with wheeze. We found an association between increased RV-specific 
IgG1 against both RV-A and RV-C, and longer time spent with reported respiratory 
symptoms at the first follow-up visit. When investigating the asthma susceptibility gene 
variant CDHR3 rs6967330 and CDHR3 mRNA expression, we found reduced mRNA levels 
in children with wheeze, especially in children with increased RV-specific IgG1 levels against 
both RV-A and RV-C at remission. One may speculate that reduced mRNA levels indicate a 
reduced cadherin production, with increased permeability of the airways through destroyed 
epithelial cell tight junctions as a consequence, leading to exaggerated inflammation and 
increased vulnerability to infection. The proposed biomarker YKL-40 did not facilitate the 
identification of children with persistent airway inflammation in this young age group with 
acute wheeze, but was correlated with levels of neutrophils in acute inflammation. 
Taken together, most of our findings indicate that children with wheeze constitute a group of 
children with an increased vulnerability, both immunologically as well as genetically, who 
are at high risk of developing asthma during later childhood.  
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9 FUTURE PERSPECTIVES 
In this study we have shown that among children with wheeze, there is a subgroup with a 
possible aberrant immune system and a genetic vulnerability that could result in an increased 
risk of later asthma development. This group of children may require close attention from an 
early age, with optimal medication and the reduction of risk factors in the environment if 
possible. Future studies will hopefully identify preventable weaknesses in the innate and 
adaptive immunity, and make it possible to decrease the number of airway infections, and 
prevent later problems with airway hyper-responsiveness, and maybe also the development of 
an airborne allergy in high-risk children with wheeze. Further studies on the effect of vitamin 
D supplementation in children with suboptimal levels in combination with symptoms of 
wheeze are needed, as well as studies on genetic variants regulating the vitamin D receptor and 
the vitamin D-binding protein. 
Research into the association of RV with asthma and allergy development will continue and 
hopefully give us tools to prevent and attenuate infections, by vaccine development, the use 
of antimicrobial peptides, or other ways to strengthen the innate immune system and 
eradicate co-infections by colonizing bacteria.  
The pursuit of easily attainable biomarkers, that reflect the progression of inflammation in the 
airways, needs to be continued and will hopefully be successful since it is important with an 
individualized assessment of inflammation, even in young children with wheeze who are at 
risk of more chronic inflammation. 
This study highlights the importance of combining genetic analyses with detailed clinical data 
from smaller selected groups of children, as a model for larger, more targeted studies.   
All children in this study are being followed until school-age with yearly follow-ups, and with 
the combined collection of clinical data, lung function measurements, as well as yearly blood 
samples they offer a valuable research material for future studies, and will contribute to our 
understanding of the interplay between environmental and genetic factors in the development 
and progression of asthma and allergy.  
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10 SAMMANFATTNING PÅ SVENSKA 
Astma är globalt sett den vanligaste kroniska sjukdomen hos barn. Antalet barn som har eller 
som insjuknar i astma har under lång tid ökat fram till 2008, nu verkar ökningen avstannat 
med sjunkande antal fall de senaste åren. (2) Många av de äldre barnen har en 
bakomliggande allergi som orsak till sin astma, men en stor andel av de yngre barnen har inte 
någon allergi men får ändå astma. (11)  
Ett av huvudsymptomen vid astma är ett visslande ljud vid utandning (eng: wheeze) 
som beror på att slemhinnan i luftrören blir svullen och inflammerad, och musklerna i 
luftrören drar ihop sig, barnen får hosta och svårt att få luft. Små förskole barn med 
förkylningsutlöst astma har ökad risk att utveckla kronisk luftrörsinflammation i skolåldern. 
(4) Vissa virus verkar vara kopplat till astma, t ex vårt vanligaste förkylningsvirus, 
Rhinovirus (RV). Oftast orsakar rhinovirus bara en lindrig snuva, men de barn som får 
förkylningsastma av rhinovirus har högre risk att ha kvar astmabesvär vid skolstart. (4) 
Ett stort antal genetiska studier har försökt att hitta genetiska varianter som ger en ökad 
risk att få astma. Det har i många fall gjorts genom att studera stora födelse grupper med 
många tusen individer för att hitta ett område eller gen på en kromosom som skiljer friska och 
sjuka individer åt. Detta har gjort att man sett hur miljöfaktorer ex cigarettrök, luftföroreningar, 
virusinfektioner kan påverka en individ som har en viss känslig genotyp att bli sjuk.  
I vår studie ingår 156 förskolebarn i åldern 6 månader till 4 år, som sökt barnakuten på 
Astrid Lindgrens Barnsjukhus i Stockholm med akuta andningsbesvär pga virus infektion 
(AW). Även 101 åldersmatchade friska kontroller (HC) utan förkylningsastma eller luftburen 
allergi inkluderades som jämförande grupp i samband med att de genomgick en mindre 
operation på dagvården. Föräldrarna till barnen i båda grupperna har svarat på frågeformulär 
angående ärftlighet för astma och allergi, miljöfaktorer som rökning under graviditet och 
tidigare luftvägsinfektioner och allergiska symptom hos barnen. Barnen har lämnat blodprover, 
AW gruppen vid tre tillfällen (akut, vid återbesök efter 2-4 månader samt efter 1 år), 
kontrollerna i samband med operationen efter att de blivit inkluderade i studien. Barnen i AW 
gruppen har dessutom tagit näsprov med avseende på virus och bakterieförekomst akut och vid 
första återbesöket efter 2-3 månader.  
 
Studie I: I den första studien ingick de 130 barn som kom tillbaka på det första 
återbesöket efter tre månader och 101 kontroller. Vi jämförde sedan tidigare kända riskfaktorer 
för astma mellan AW och HC grupperna, inklusive antikroppar mot luftburna allergen (björk, 
timotej, gråbo, katt, hund, häst, mögel och kvalster) och födoämnesallergen (komjölk, ägg, 
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soja, jordnöt, torsk, vete). Vitamin D nivåer i blodet analyserades också, då studier har visat att 
låga D-vitamin nivåer ger ökad risk för återkommande virusinfektioner, (20) och astma. (21, 
22)   
Vi fann att barn i AW gruppen hade flera riskfaktorer för astma jämfört med kontrollerna 
(ökad ärftlighet för astma/allergi, fler mammor som rökte under graviditeten, mindre tid med 
enbart amning utan samtidig komjölksbaserad ersättning, flera som gick på förskolan). AW 
gruppen hade också lägre nivåer av vitamin D, betydligt fler luftvägsinfektioner samt 
rapporterade mer födoämnesreaktioner än HC gruppen.  
 
Studie II: Det finns tre typer av rhinovirus: RV-A, RV-B och RV-C. Det är framför allt 
RV-A och RV-C som man hittar hos barn som söker med andningssvårigheter på 
akutmottagningen. Vissa studier anser att RV-C är mer sjukdomsframkallande, andra studier 
visar att RV-A och RV-C ger lika mycket besvär.  I den andra studien tittade vi på vilka typer 
av RV barnen hade vid akutbesöket samt om nivåerna av RV specifika antikroppar ökade vid 
återbesöket jämfört med nivåerna vid akutbesöket. RV var vanligt, och hittades hos 75 % av 
barnen, RV-C var vanligast (74% av barnen där vi hittade RV). Vi såg ingen koppling mellan 
RV typ vid det akuta besöket och hur länge barnen var sjuka eller använde astmamediciner. 
Barn med ökning av antikroppar mot både RV-A och RV-C vid återbesöket hade haft mest 
luftvägssymtom, vilket kanske beror på en förstärkt effekt av flera virus samtidigt och en 
svårare inflammation.  
 
Studie III: RV-A och RV-B upptäcktes på 50-talet, RV-C upptäckte man runt 2006. 
Man har inte förrän nyligen vetat hur RV-C fäster till cellerna i luftvägarna och orsakar 
infektion, men nu har man upptäckt proteinet som fungerar som receptor, (cadherin-related 
family member 3). Genen som kodar för det proteinet heter CDHR3. I en stor studie på flera 
tusen barn (Genome Wide Association Study, GWAS) kopplade man nyligen en genetisk 
variant av genen (CDHR3 rs6967330 G>A) till förkylningsastma hos förskolebarn. Vi 
analyserade DNA från blod på AW och HC gruppen och jämförde förekomsten av den 
genvarianten, och såg att barnen i AW gruppen hade betydligt fler med riskvarianten. 
 Vi jämförde också nivåerna av budbärar RNA (mRNA, av engelskans messenger-RNA) 
i två mindre grupper (50 barn från AW gruppen och 17 barn från HC gruppen) Budbärar-RNA 
för över information från DNA i cellkärnan och deltar sedan i framställning av protein-
molekyler i cellen. Barnen som hade risk varianten av genen visade betydligt lägre nivåer av 
mRNA både akut och vid första återbesöket jämfört med kontrollerna. Den RV typ som barnen 
hade då de var på akutbesöket verkade inte påverka mRNA nivåerna, men barnen med 
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förhöjda RV-specifika antikroppar mot både RV-A och RV-C när de kom på återbesöket efter 
ett par månader hade lägst mRNA nivåer jämfört med barn med antikroppar mot bara ett RV. 
Om lägre mRNA nivåer betyder att det bildas mindre protein, kan det innebära en ökad 
genomsläpplighet och känslighet i luftvägarnas slemhinnor vid RV infektion, med en svårare 
inflammation i luftvägarna som följd.   
 
Studie IV: I den fjärde studien har vi tittat på nivåerna av ett visst protein som kallas för 
YKL-40. Höga nivåer av det proteinet har hittats i blodet hos många individer som har olika 
kroniska inflammationer, och också hos barn och vuxna med svår astma. (58-60) Protein 
produktionen styrs av en gen (CHI3L1 (Chitinase-3-like-1)) Det finns flera genvarianten som 
påverkar YKL-40 nivåerna och genvarianten CHI3L1 rs4950928 (C/G) har visat sig vara en 
sådan. Vi undersökte hur genvarianterna var fördelade i AW gruppen och HC gruppen, och 
fann inte någon skillnad. Vi jämförde också nivåerna av YKL-40 i plasma hos AW gruppen 
vid akut besök, återbesök efter tre månader och efter ett år och kontrollgruppen. YKL-40 
nivåerna var högre i AW gruppen vid de två första besöken, men på samma nivå som 
kontrollerna vid årsbesöket då det inte var någon skillnad. Nivån av YKL-40 var kopplat till  
antalet vita blodkroppar (neutrofiler) i blodet, och kan vara en reflektion av en pågående icke 
allergisk inflammation. (60, 61) 
 
Sammanfattningsvis har vi i denna studie följt en grupp barn med återkommande obstruktiva 
besvär vid infektioner, och de uppvisar flera riskfaktorer både ärftliga och miljö faktorer men 
också en immunologisk och genetisk känslighet jämfört med en grupp friska kontroller utan 
obstruktiva besvär. 
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